Raschi, E., Piccinni, C., Poluzzi E., et al.: The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol., 2013, 50(4), 569–577.

Faillie, J. L., Babai, S., Crepin, S., et al.: Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol., 2014, 51(3), 491–497.

Dore, D. D., Seeger, J. D., Arnold Chan, K.: Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr. Med. Res. Opin., 2009, 25(4), 1019–1027.

Garg, R., Chen, W., Pendergrass, M.: Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care, 2010, 33(11), 2349–2354.

Dore, D. D., Bloomgren, G. L., Wenten, M., et al.: A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes. Metab., 2013, 13(6), 559–566.

Romley, J. A., Goldman, D. P., Solomon, M., et al.: Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol. Ther., 2012, 14(10), 904–911.

Wenten, M., Gaebler, J. A., Hussein, M., et al.: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet. Med., 2012, 29(11), 1412–1418.

Eurich, D. T., Simpson, S., Senthilselvan, A., et al.: Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ, 2013, 346, f2267.

Funch, D., Gydesen, H., Tornøe, K., et al.: A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes. Metab., 2014, 16(3), 273–275.

Giorda, C. B., Picariello, R., Nada, E., et al.: Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol., 2014, 2(2), 111–115.

Faillie, J. L., Azoulay, L., Patenaude, V., et al.: Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ, 2014, 348, g2780.

Chou, H. C., Chen, W. W., Hsiao, F. Y.: Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug Saf., 2014, 37(7), 521–528.

Thomsen, R. W., Pedersen, L., Møller, N., et al.: Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care, 2015, 38(6), 1089–1098.

Gonzalez-Perez, A., Schlienger, R. G., Rodríguez, L. A.: Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care, 2010, 33(12), 2580–2585.

Butler, P. C., Elashoff, M., Elashoff, R., et al.: A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care, 2013, 36(7), 2118–2125.

Butler, A. E., Campbell-Thompson, M., Gurlo, T., et al.: Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 2013, 62(7), 2595–2604.

Nauck, M. A.: A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care, 2013, 36(7), 2126–2132.

Cefalu, W. T., Rosenstock, J., Henry, R. R., et al.: Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance. Diabetes Care, 2013, 36(7), 1804–1806.

Bonner-Weir, S., In’t Veld, P. A., Weir, G. C.: Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes. Metab., 2014, 16(7), 661–666.

ADA/EASD/IDF Recommendations for clinicians and people with diabetes concerning the use of incretin therapy and pancreatic disease. http://www.easd.org

Egan, A. G., Blind, E., Dunder, K., et al.: Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N. Eng. J. Med., 2014, 370(9), 794–797.

Matveyenko, A. V., Dry, S., Cox, H. I., et al.: Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes, 2009, 58(7), 1604–1615.

Scirica, B. M., Bhatt, D. L., Braunwald, E., et al.: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med., 2013, 369(14), 1317–1326.

White, W. B., Cannon, C. P., Heller, S. R., et al.: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med., 2013, 369(14), 1327–1335.

Green, J. B., Bethel, M. A., Armstrong, P. W., et al.: Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2015, 373(3), 232–242.

Pfeffer, M. A., Claggett, B., Diaz, R., et al.: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med., 2015, 373(23), 2247–2257.

Monami, M., Dicembrini, I., Nardini, C., et al.: Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res. Clin. Pract., 2014, 103(2), 269–275.

Li, L., Shen, J., Bala, M. M., et al.: Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ, 2014, 348, g2366.

Azoulay, L.: Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes Care, 2015, 38(6), 951–953.